Brief: Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study
07/04/2025 11:03
April 7 (Reuters) - Lexeo Therapeutics Inc LXEO.O: LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1/2 DATA FOR LX2006 IN FRIEDREICH ATAXIA CARDIOMYOPATHY SUPPORTING ADVANCEMENT TO REGISTRATIONAL STUDY LEXEO THERAPEUTICS INC: LX2006 GENERALLY WELL TOLERATED WITH NO SIGNS OF COMPLEMENT ACTIVATION OR OTHER IMMUNOGENICITY TO DATE LEXEO THERAPEUTICS : PARTICIPANTS WITH ABNORMAL LEFT VENTRICULAR MASS INDEX AT BASELINE ACHIEVED 25% MEAN REDUCTION IN LVMI BY 12 MONTHS OR SOONER LEXEO THERAPEUTICS : CLINICALLY MEANINGFUL IMPROVEMENTS IN MAJORITY OF PARTICIPANTS ACROSS CARDIAC BIOMARKERS & FUNCTIONAL MEASURES Source text: ID:nGNX4F00MX Further company coverage: LXEO.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease